Health Care · Life Sciences Tools

10x Genomics, Inc. TXG

$47.63-1.80 (-3.64%)delayed quote · as of 2026-07-31 19:14 UTC

Open TXG in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$6.0B

Previous close

$49.43

Volume

1.6M

52-week range

$11.16 – $50.34

Verdictconfidence 81% · high

Growth, Health and Momentum stand out; value flashes caution.

4 of 5 dimensions score well; value flashes caution.

Value00/4 checks

Growth753/4 checks

Quality502/4 checks

Health1003/3 checks

Momentum1005/5 checks

Fair-value estimate $3.86 per share (2-stage FCF · individual beta · 10Y Rf 4.7%) — the price sits 1133% above it.

Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.

Key ratioslatest filing FY 2025

Value

P/E TTM

—

P/E FWD

230.5

EV/EBITDA TTM

—

PEG

—

FCF yield TTM

2.0%

Growth

Revenue 3y

+7.6%/yr

Revenue YoY

+5.2%

Expected EPS

—

Quality

Piotroski F

5 / 9

ROIC

—

Gross margin

69.0%

Health

Altman Z

13.81

Current ratio

4.46

Debt/equity

—

Momentum

vs 50-day

+137.1%

vs 200-day

+195.4%

52-wk range

93%

FY 2025: revenue $642.8M · net income -$43.5M · free cash flow $130.1M (SEC EDGAR filings)

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-07-31 19:14 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading TXG’s filed statements…

Continue with TXG in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.